AVIPERO is developing unique allosteric modulators of integrins for Triple Negative Breast Cancer AVIPERO has unique Platform technology with multiple applications/indications. AVIPERO is a strong team with track record in drug development in cancer. At Avipero we aspire to revolutionize the treatment of malignant and degenerative diseases worldwide. We are dedicated to the study of breast cancer, our pharmaceutical research company prioritizes the development of a non-destructive cure for this metastatic disease.
View Top Employees from AVIPERO Ltd.| Website | http://www.avipero.com |
| Revenue | $1 million |
| Employees | 7 (1 on RocketReach) |
| Founded | 2009 |
| Address | 125 Princes St, Edinburgh, Edinburgh EH2 4AD, GB |
| Technologies | |
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Competitors | Curileum Discovery Ltd, OCKHAM BIOTECH LIMITED, Oxford BioDynamics Plc, Scancell Ltd, Tristem Corp |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541711 Companies, NAICS Code 54171 Companies |
Looking for a particular AVIPERO Ltd. employee's phone or email?
AVIPERO Ltd. Questions
The AVIPERO Ltd. annual revenue was $1 million in 2024.
Rehab AlJamal-Naylor is the Chief Scientific Officer of AVIPERO Ltd..
1 people are employed at AVIPERO Ltd..
AVIPERO Ltd. is based in Edinburgh, Edinburgh.
The NAICS codes for AVIPERO Ltd. are [5417, 54, 541, 541711, 54171].
The SIC codes for AVIPERO Ltd. are [28, 283, 80].
Top AVIPERO Ltd. Employees
Related Companies
